Advanced search
Publication Cover
Modern Rheumatology Volume 20, 2010 - Issue 2
Journal homepage
19
Views
8
CrossRef citations to date
0
Altmetric
Case Report

Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab

Akinori YamamotoDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Kojiro SatoDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, JapanCorrespondence[email protected]
,
Fumihiko MiyoshiDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Yasufumi ShindoDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Yoshihiro YoshidaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Kazuhiro YokotaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Kyoichi NakajimaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Haruhiko AkibaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Yu AsanumaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
,
Yuji AkiyamaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
&
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
 show all
Pages 183-187 | Received 11 Mar 2009, Accepted 01 Oct 2009, Published online: 02 Jan 2014

References

  • Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–10.
  • Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–7.
  • Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9.
  • Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: 987–97.
  • Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
  • Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652–61.
  • Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–81.
  • Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417–23.
  • Sato K. Th17 cells and rheumatoid arthritis—from the standpoint of osteoclast differentiation. Allergol Int. 2008;57:109–14.
  • Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–52.
  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breed-veld FC, Kalden JR, et al. Infiiximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.
  • Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146–54.
  • Harris J, Vaughan JH. Transfusion studies in rheumatoid arthritis. Arthritis Rheum. 1961;4:47–55.
  • Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806.
  • Manzo A, Pitzalis C. Lymphoid tissue reactions in rheumatoid arthritis. Autoimmun Rev. 2007;7:30–4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.